VSTM Multiplikator Forward P/S Verastem

Verastem, Inc. (VSTM) currently has no commercial sales, however, the future launch of targeted drugs will enable premium pricing. High pricing power is expected due to avutometinib, which blocks tumor regeneration. The future P/S multiple valuation on GURU.Markets confirms long-term sustainability, where the latest value is recorded as 10.60. Proprietary developments will allow the company to monetize proven oncology therapy courses for years.

VSTM (verastem.com) riwayat Rasio rega marang pendapatan sing dikarepake saka 04.07.2022 nganti 13.11.2026

Verastem Corp - rincian analitis lan metrik utama (VSTM)

- rega saiki lan proyeksi nilai saham:

Rega saham Verastem|VSTM - Rentang target analis

- data kapitalisasi pasar:

Kapitalisasi pasar Verastem Corp|VSTM - Total Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham Verastem|VSTM - Total Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku verastem.com|VSTM - Aset Perusahaan

- data utang lan likuiditas:

- indikator pendapatan resik lan kelipatan nilai:

VSTM - Penghasilan resik perusahaan|Bathi sing dikarepake Verastem, Inc.|VSTM - Nilai perusahaan marang bathi resik|Pangali Forward P/E Verastem Inc|VSTM - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Verastem Corp|VSTM - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Verastem|VSTM - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan verastem.com|VSTM - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Verastem, Inc.

- rincian pendapatan lan dodolan emiten:

VSTM - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan Verastem|VSTM - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Verastem Corp

Ringkesan analisis perusahaan:Verastem (VSTM)

The forward P/S ratio reflects the market value of a business relative to its projected annual revenue. By analyzing the forward P/S trend, an investor determines the extent of the premium paid for future cash flows. The metric is calculated as the ratio of current market capitalization to expected sales volume. For Verastem, Inc. (VSTM), this indicator is critical, as it assesses the speculative value of the R&D pipeline and the probability of success for avutometinib therapy.

Perusahaan pesaing

Multiplikator Forward P/S GMAB (Genmab)|Prakiraan rega marang pendapatan Exelixis Inc|Nuvalent Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kymera Corp|IDYA (IDEAYA Biosciences) - Multiplikator forward rega marang pendapatan|ELVN: Rasio rega marang pendapatan sing dikarepake|ORIC (ORIC Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Relay Therapeutics Inc RLAY|Multiplikator Forward P/S NRIX|Tyra Corp - Kapitalisasi marang prakiraan pendapatan|Monte Rosa Therapeutics - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CGEM|IMRX: Multiplikator forward rega marang pendapatan|C4 Therapeutics Inc - Rasio rega marang pendapatan sing dikarepake|BDTX: Multiplikator Forward P/S|Repare Therapeutics Inc - Rega forward marang dodolan|PMVP (PMV Pharmaceuticals) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Karyopharm KPTI|Rasio rega marang prakiraan pendapatan Propanc Biopharma Inc (PPCB)|BGMS (Bio Green Med Solution Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S AADI (Aadi Bioscience, Inc.)|Multiplikator Forward P/S Aileron Therapeutics Inc ALRN|BPMC - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan GLYC|SWTX (SpringWorks Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan